Company Filing History:
Years Active: 2006
Title: The Innovative Contributions of Jean-Yves Marcel Paul Bonnefoy
Introduction
Jean-Yves Marcel Paul Bonnefoy is a notable inventor based in Le Sappey, France. He has made significant strides in the field of biotechnology, particularly through his work on antibodies that play crucial roles in therapeutic applications. His research and innovations are pivotal in advancing treatments for various autoimmune and inflammatory disorders.
Latest Patents
Bonnefoy holds a patent for "Antibodies to CD23, derivatives thereof, and their therapeutic uses." This invention focuses on antibodies that bind to the CD23 (FCεRII) type II molecule, including altered antibodies with an affinity constant equal to or greater than 1×10^Ka Mol. The patent also encompasses the preparation of such antibodies, the pharmaceutical compositions that incorporate them, and their application in therapeutic settings. This innovation represents a significant advancement in medical therapies aimed at treating complex health issues.
Career Highlights
Jean-Yves Marcel Paul Bonnefoy works with Glaxo Wellcome Inc., where he has been influential in the development of therapeutic antibodies. His expertise and contributions have made him a key figure in the research community, particularly in the realms of immunology and therapeutic interventions.
Collaborations
Throughout his career, Bonnefoy has collaborated with esteemed colleagues such as James Scott Crowe and Jonathan Henry Ellis. These partnerships have fostered a collaborative environment that enhances the research and development of innovative therapeutic solutions.
Conclusion
In summary, Jean-Yves Marcel Paul Bonnefoy is a distinguished inventor whose work in antibody research has significant implications for treating autoimmune and inflammatory disorders. His patent and collaborations underscore his dedication to advancing medical science and improving therapeutic options for patients.